CRDF · XBRL financial data

Cardiff Oncology financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CRDF's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	366	—	—	—	—	—
Revenue from contracts with customers	366	359	386	488	683	593
Research and development	11,235	17,400	27,100	—	—	—
Selling, general and administrative	8,216	11,838	13,181	13,043	12,482	14,224
Total operating expenses	19,452	29,214	40,288	45,900	49,334	49,553
Other operating income (expense)	(28)	—	—	—	—	—
Operating income (loss)	(19,086)	(28,855)	(39,902)	(45,412)	(48,651)	(48,960)
Interest income	90	264	1,581	4,069	3,259	3,104
Interest expense	2	0	—	—	—	—
Other income (expense)	—	—	—	(98)	(39)	5
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(19,307)	(28,291)	(38,704)	(41,441)	(45,431)	(45,851)
Earnings per share, basic USD per share	(1.08)	(0.73)	(0.89)	(0.93)	(0.95)	(0.69)
Earnings per share, diluted USD per share	(1.08)	(0.73)	(0.89)	(0.93)	(0.95)	(0.69)
Weighted average shares, basic thousands of shares	20,875	39,030	43,600	44,677	47,650	66,841
Weighted average shares, diluted thousands of shares	20,875	39,030	43,600	44,677	47,650	66,841

Fiscal years (CRDF's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	130,981	11,943	16,347	21,655	51,470	17,470
Short-term investments	0	128,878	88,920	53,168	40,276	40,834
Marketable securities	—	95,584	83,924	26,309	34,005	31,947
Marketable securities, non-current	—	33,294	4,996	26,859	6,271	8,887
Accounts receivable	320	535	771	288	773	182
Prepaid and other current assets	2,055	4,771	5,246	2,301	—	—
Total current assets	133,356	146,127	111,284	77,412	95,054	60,128
Property and equipment, net	624	382	1,269	1,238	898	578
Right-of-use asset	343	2,796	2,251	1,708	1,169	629
Total assets	134,727	149,544	116,191	81,637	97,190	61,884
Accounts payable	1,366	1,439	1,956	1,966	4,821	8,087
Accrued liabilities	3,851	4,527	5,177	7,783	7,897	7,577
Total current liabilities	6,119	6,559	7,808	10,440	13,428	16,394
Lease liability, non-current	9	2,568	2,040	1,458	813	102
Total liabilities	6,570	9,127	9,848	11,898	14,241	16,496
Accumulated deficit	(231,495)	(259,810)	(298,100)	(339,541)	(384,179)	(430,030)
Total stockholders' equity	128,158	140,417	106,343	69,739	82,949	45,388
Total liabilities and equity	134,727	149,544	116,191	81,637	97,190	61,884
Common shares outstanding (cover page) thousands of shares	37,052	43,306	44,677	44,677	66,524	68,365

Fiscal years (CRDF's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(19,307)	(28,291)	(38,704)	(41,441)	(45,431)	(45,851)
Stock-based compensation	1,765	3,234	4,256	4,509	4,760	5,693
Depreciation and amortization	466	451	236	398	404	364
Net cash from operating activities	(16,315)	(23,040)	(33,820)	(30,887)	(37,693)	(37,923)
Purchases of property and equipment	212	205	1,006	582	80	44
Net cash from investing activities	(212)	(131,448)	38,149	36,195	13,728	1,342
Proceeds from issuing common stock	112,300	34,187	0	—	53,407	0
Proceeds from long-term debt	305	0	—	—	—	—
Net cash from financing activities	137,312	35,450	75	0	53,780	2,581
Net change in cash	120,785	(119,038)	4,404	5,308	29,815	(34,000)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Cardiff Oncology	9,197	104	(11,765)*	77.8M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Silence Therapeutics	72,054	0	1,518*	141.7M	—	Q2 FY26 10-QJun 30, 2026
Rezolute	10,615	not reported	(13,146)*	96.7M	8.2 quarters	Q4 FY26 10-KJun 30, 2026
Tvardi Therapeutics	15,765	not reported	(9,228)*	13.3M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Natures Sunshine Products	82,503	116,985	835*	17.6M	—	Q2 FY26 10-QJun 30, 2026
Rocket Pharmaceuticals	224,507	0	(39,613)*	109.8M	7.2 quarters	Q2 FY26 10-QJun 30, 2026
Esperion Therapeutics	156,158	80,104	(27,722)	257.4M	5.6 quarters	Q1 FY26 10-QMar 31, 2026
Perspective Therapeutics	48,488	not reported	(20,650)*	114.2M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Palvella Therapeutics	187,803	not reported	(12,845)*	14.4M	19.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.